Evidence map›Paper›PMID 42440520›Full record

ArticleMolecular therapy. Oncology2026

Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.

Dana Cholujova, Zuzana Valuskova, Monika Burikova, Milan Hucko, Gabor Beke, Eva Sedlackova, Lubos Klucar, Katarina Suroviakova, Gabriela Grofova, Jan Sedlak and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dana CholujovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Zuzana ValuskovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Monika BurikovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Milan HuckoCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Gabor BekeInstitute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 84551 Bratislava, Slovakia.
Eva SedlackovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Lubos KlucarInstitute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 84551 Bratislava, Slovakia.
Katarina SuroviakovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Gabriela GrofovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Jan SedlakCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
Jana JakubikovaCancer Research Institute, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a plasma-cell malignancy driven by dysregulated NF-κB signaling, promoting tumor survival, proliferation, and chemoresistance. Given observed overexpression of NF-κB components in MM cell lines, we evaluated the selective NF-κB inhibitor QNZ (EVP4593) for anti-myeloma activity. QNZ selectively reduced viability and inhibited proliferation of MM cells

Indexed as

EVP4593multiple myelomaNF-κB signalingthe selective NF-κB inhibitor QNZtumor microenvironment

Identifiers

PMID42440520
PMCPMC13333365

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.